Microparticulated anti-HIV vaginal gel: In vitro-in vivo drug release and vaginal irritation study

Arkendu Chatterjee, Lalit Kumar, Benoy Brata Bhowmik, Amlan Gupta

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The aim of this study was to develop and evaluate a Zidovudine (AZT)-loaded microparticulated bioadhesive vaginal gel (MBVG) in order to obtain a controlled releasing, safe gel delivery system. AZT microparticles (ZMPs) were evaluated for encapsulation efficiency, drug loading, surface morphology and in vitro drug release profiles and drug release mechanism and optimized. The optimized ZMPs were then encompassed in bioadhesive gel using different bioadhesive polymers and evaluated for the drug encapsulation efficiency, drug loading, in vitro and in vivo drug release profiles, drug release mechanism and vaginal irritancy study. From the dissolution data of ZMP4 and MBVG4 showed a zero-order diffusion pattern and Fickian diffusion case I transport mechanism in 24 and 36h, respectively. On the basis of a pharmacokinetic study of MBVG4 (containing ZMP: Carbopol 1:4), it was found to have better bioavailability, larger AUC and T max in comparison to an oral pure suspension of AZT.

Original languageEnglish
Pages (from-to)466-473
Number of pages8
JournalPharmaceutical Development and Technology
Volume16
Issue number5
DOIs
Publication statusPublished - 01-10-2011

Fingerprint

Foams and Jellies Vaginal Creams
HIV
Gels
Pharmaceutical Preparations
Zidovudine
Biological Availability
Area Under Curve
Suspensions
Polymers
Pharmacokinetics
Drug Liberation
In Vitro Techniques
AICA ribonucleotide

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Chatterjee, Arkendu ; Kumar, Lalit ; Bhowmik, Benoy Brata ; Gupta, Amlan. / Microparticulated anti-HIV vaginal gel : In vitro-in vivo drug release and vaginal irritation study. In: Pharmaceutical Development and Technology. 2011 ; Vol. 16, No. 5. pp. 466-473.
@article{ddca14c64bce41eaa5183087eba8d751,
title = "Microparticulated anti-HIV vaginal gel: In vitro-in vivo drug release and vaginal irritation study",
abstract = "The aim of this study was to develop and evaluate a Zidovudine (AZT)-loaded microparticulated bioadhesive vaginal gel (MBVG) in order to obtain a controlled releasing, safe gel delivery system. AZT microparticles (ZMPs) were evaluated for encapsulation efficiency, drug loading, surface morphology and in vitro drug release profiles and drug release mechanism and optimized. The optimized ZMPs were then encompassed in bioadhesive gel using different bioadhesive polymers and evaluated for the drug encapsulation efficiency, drug loading, in vitro and in vivo drug release profiles, drug release mechanism and vaginal irritancy study. From the dissolution data of ZMP4 and MBVG4 showed a zero-order diffusion pattern and Fickian diffusion case I transport mechanism in 24 and 36h, respectively. On the basis of a pharmacokinetic study of MBVG4 (containing ZMP: Carbopol 1:4), it was found to have better bioavailability, larger AUC and T max in comparison to an oral pure suspension of AZT.",
author = "Arkendu Chatterjee and Lalit Kumar and Bhowmik, {Benoy Brata} and Amlan Gupta",
year = "2011",
month = "10",
day = "1",
doi = "10.3109/10837450.2010.485318",
language = "English",
volume = "16",
pages = "466--473",
journal = "Pharmaceutical Development and Technology",
issn = "1083-7450",
publisher = "Informa Healthcare",
number = "5",

}

Microparticulated anti-HIV vaginal gel : In vitro-in vivo drug release and vaginal irritation study. / Chatterjee, Arkendu; Kumar, Lalit; Bhowmik, Benoy Brata; Gupta, Amlan.

In: Pharmaceutical Development and Technology, Vol. 16, No. 5, 01.10.2011, p. 466-473.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Microparticulated anti-HIV vaginal gel

T2 - In vitro-in vivo drug release and vaginal irritation study

AU - Chatterjee, Arkendu

AU - Kumar, Lalit

AU - Bhowmik, Benoy Brata

AU - Gupta, Amlan

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The aim of this study was to develop and evaluate a Zidovudine (AZT)-loaded microparticulated bioadhesive vaginal gel (MBVG) in order to obtain a controlled releasing, safe gel delivery system. AZT microparticles (ZMPs) were evaluated for encapsulation efficiency, drug loading, surface morphology and in vitro drug release profiles and drug release mechanism and optimized. The optimized ZMPs were then encompassed in bioadhesive gel using different bioadhesive polymers and evaluated for the drug encapsulation efficiency, drug loading, in vitro and in vivo drug release profiles, drug release mechanism and vaginal irritancy study. From the dissolution data of ZMP4 and MBVG4 showed a zero-order diffusion pattern and Fickian diffusion case I transport mechanism in 24 and 36h, respectively. On the basis of a pharmacokinetic study of MBVG4 (containing ZMP: Carbopol 1:4), it was found to have better bioavailability, larger AUC and T max in comparison to an oral pure suspension of AZT.

AB - The aim of this study was to develop and evaluate a Zidovudine (AZT)-loaded microparticulated bioadhesive vaginal gel (MBVG) in order to obtain a controlled releasing, safe gel delivery system. AZT microparticles (ZMPs) were evaluated for encapsulation efficiency, drug loading, surface morphology and in vitro drug release profiles and drug release mechanism and optimized. The optimized ZMPs were then encompassed in bioadhesive gel using different bioadhesive polymers and evaluated for the drug encapsulation efficiency, drug loading, in vitro and in vivo drug release profiles, drug release mechanism and vaginal irritancy study. From the dissolution data of ZMP4 and MBVG4 showed a zero-order diffusion pattern and Fickian diffusion case I transport mechanism in 24 and 36h, respectively. On the basis of a pharmacokinetic study of MBVG4 (containing ZMP: Carbopol 1:4), it was found to have better bioavailability, larger AUC and T max in comparison to an oral pure suspension of AZT.

UR - http://www.scopus.com/inward/record.url?scp=80052884601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052884601&partnerID=8YFLogxK

U2 - 10.3109/10837450.2010.485318

DO - 10.3109/10837450.2010.485318

M3 - Article

C2 - 20497098

AN - SCOPUS:80052884601

VL - 16

SP - 466

EP - 473

JO - Pharmaceutical Development and Technology

JF - Pharmaceutical Development and Technology

SN - 1083-7450

IS - 5

ER -